Bromocriptine 5mg BID for Lowering Prolactin Levels
Do not start bromocriptine at 5 mg twice daily—this dose is too high and violates FDA-approved dosing protocols. The correct approach is to start at 1.25-2.5 mg once daily with food and titrate gradually every 2-7 days to minimize side effects and optimize therapeutic response 1.
Critical Dosing Error to Avoid
Starting at 5 mg BID (10 mg/day total) bypasses the essential titration phase and significantly increases the risk of intolerable side effects, particularly nausea, vomiting, and orthostatic hypotension. This approach contradicts both FDA labeling and clinical practice guidelines.
Correct Initiation Protocol
Starting Dose
- Begin with 1.25-2.5 mg once daily with food (one-half to one 2.5 mg tablet) 1
- Always administer with food to reduce gastrointestinal side effects
- Take at bedtime initially to minimize orthostatic symptoms
Titration Schedule
- Add 2.5 mg every 2-7 days as tolerated until optimal therapeutic response is achieved 1
- Evaluate patients frequently during dose escalation to determine the lowest effective dose
- The therapeutic range for hyperprolactinemia is typically 2.5-15 mg daily in adults 1
Monitoring Strategy
First Month:
- Check serum prolactin at 1 month after starting therapy to guide dose adjustments 2
- Assess for symptom improvement (galactorrhea resolution, menstrual cycle restoration)
- Monitor for side effects (nausea, dizziness, headache)
Ongoing Monitoring:
- Repeat MRI at 1 year for microadenomas, or at 3 months for macroadenomas if prolactin continues rising or new symptoms develop 2
- Visual field examinations for macroadenomas at risk of optic chiasm compression 2
- Assess for hypogonadism reversal and bone health
Why Cabergoline is Preferred
The Endocrine Society strongly recommends cabergoline over bromocriptine as first-line therapy 2. Cabergoline demonstrates:
- Higher efficacy in normalizing prolactin (92-95% vs. 68-80% with bromocriptine) 2, 3
- Superior tumor shrinkage (90% vs. 50% reduction) 2
- Better tolerability (12% vs. 53% adverse events) 3
- More convenient dosing (twice weekly vs. daily)
If bromocriptine must be used due to cabergoline unavailability, the gradual titration approach becomes even more critical for tolerability.
Resistance Management
If standard doses fail to normalize prolactin or reduce tumor size:
- Increase the bromocriptine dose rather than immediately referring for surgery 2
- Switch to cabergoline if bromocriptine resistance occurs 2
- Consider intravaginal bromocriptine administration for patients intolerant of oral formulation 2
Special Populations
Pregnancy:
- Discontinue bromocriptine immediately upon pregnancy confirmation for microadenomas 2
- For macroadenomas abutting the optic chiasm, continuing therapy throughout pregnancy may be prudent 2
- Bromocriptine is the preferred dopamine agonist if treatment during pregnancy is necessary 2
Children (ages 11-15):
- Same starting dose: 1.25-2.5 mg daily
- Therapeutic range: 2.5-10 mg daily 1
Common Pitfalls
- Starting too high: The 5 mg BID dose you mentioned would cause immediate intolerance in most patients
- Inadequate food co-administration: High vomiting rates occur with fasting administration 1
- Premature discontinuation: Symptoms return in the majority after withdrawal, even after years of treatment 4
- Ignoring dose titration based on prolactin response: Some patients normalize on as little as 2.5 mg daily 5, 6